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Introduction
Erythema elevatum diutinum (EED) is a rare, chronic 
leukocytoclastic vasculitis characterized by firm, red, 
violaceous, or brown papules and nodules on the 
extensor surfaces of the limbs. As with most rare 
diseases, data on therapeutic effectiveness is sparse, 
but oral dapsone is currently considered first-line 
therapy [2] and was shown to be effective in 80% of 
EED cases [1]. However, dapsone may not be effective 
in certain EED presentations (e.g. fibrotic nodules) or 
tolerated in certain patient populations (e.g. those 
with renal or hepatic impairment, G6PD deficiency, 
anemia), [1,3]. We report a patient with complete 
resolution of EED using sulfasalazine.
Case Synopsis
A 35-year old woman with a one-year history of 
worsening joint pain of the hands, knees, ankles, and 
feet was referred by the emergency department for a 
rash. At presentation to the dermatology outpatient 
clinic, the patient reported pain in her right third 
metacarpophalangeal joint (MCP) and small, mildly 
tender nodules over her right thumb, right fifth digit, 
right third MCP, left hand, left elbow, and lateral 
tongue. She reported a history of blue discoloration 
of her right second and third fingertips, which 
progressed to redness and swelling. Additionally, she 
reported headaches distinct from past migraines. 
The differential diagnosis, based on clinical findings, 
included perniosis in the setting of systemic lupus 
erythematosus (SLE), neutrophilic dermatosis, or 
localized vasculitis. Although SLE would explain 
her joint pain, it was clinically unlikely owing to a 
negative review of systems (ROS), including absence 
of photosensitivity, malar rashes, nephritis, pleurisy, 
blood clots, and gastrointestinal problems. Given 
the classic appearance and distribution of localized 
nodules, EED was suspected.
Laboratory results showed a complete blood count 
and basic metabolic panel within normal limits, 
calcium: 9.2 (8.5-10.9 mg/dL), and total protein: 6.8 
(6.3-7.9 g/dL). Laboratory results were also negative 
for anti-double stranded deoxyribonucleic acid (anti-
dsDNA), antinuclear antibodies, anti-Scl-70, anti-
Ro/La, serum protein electrophoresis, and relevant 
urinalyses. The patient had no known risk factors for 
human immunodeficiency virus (HIV) or hepatitis, 
but an HIV and hepatitis screen were negative in 
the emergency room (ER) immediately prior to the 
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considered first-line therapy for EED; in the current 
case report, a patient presenting with EED began 
dapsone treatment and symptoms subsided 
within two weeks. Seven months later, the patient 
became pregnant and stopped dapsone owing to 
her concerns with dapsone use during pregnancy, 
resulting in recurrence of EED symptoms. We present 
a novel treatment approach with oral sulfasalazine, 
which was given to the patient in lieu of dapsone and 
resulted in complete resolution of EED symptoms.
Volume 23 Number 10 | October 2017 
DOJ 23 (10): 22
- 2 - 
Dermatology Online Journal  ||  Letter
dermatology outpatient clinic visit. Both a magnetic 
resonance imaging scan of the head and a chest X-ray 
in the ER were unremarkable. The patient reported 
no symptoms of streptococcal infections and had no 
clinical history or any indication on exam; because the 
condition had been on-going, antistreptolysin O titer 
was not felt to be needed clinically. With a negative 
ROS for the relevant conditions and the work-up to 
date, anti-neutrophil cytoplasmic antibodies (ANCA) 
and antiphospholipid antibodies were not indicated.
A skin biopsy was performed on the right fifth 
digit (Figure 1) and histopathology showed an 
acanthotic epidermis and underlying diffuse 
infiltrate of neutrophils in the dermis (Figure 2). 
Features of vasculitis such as fibrinoid necrosis of 
vessel walls were not seen (Figure 3). The histologic 
differential diagnosis of EED includes other 
neutrophilic dermatoses such as leukocytoclastic 
vasculitis, granuloma faciale, and Sweet syndrome. 
Leukocytoclastic vasculitis was excluded because of 
the absence of vasculitis and the well-established 
EED lesions exhibiting a more diffuse dermal 
infiltrate of neutrophils [4]. Granuloma faciale was 
clinically unlikely because extrafacial manifestation 
is uncommon [5]. Granuloma faciale would be 
characterized by a well-established Grenz zone, 
sparing of hair follicles, and a higher proportion 
of eosinophils compared to neutrophils. Sweet 
syndrome was excluded owing to lack of papillary 
dermal edema and a denser infiltrate of neutrophils. 
These histopathologic findings with the clinical 
presentation supported a diagnosis of EED.
The patient began oral dapsone treatment with no 
EED flares following the second week of treatment. 
Seven months later, the patient became pregnant 
and stopped dapsone (pregnancy category C) 
treatment, as she was concerned with dapsone use 
in pregnancy. Within three days, the patient reported 
recurrence of extreme pain, swelling in the hands, 
and an inability to perform daily functions, sleeping 
fewer than two hours per night because of extreme 
pain.
Treatment with oral sulfasalazine was suggested to 
the patient. Soon after initiation of sulfasalazine, the 
patient reported full remission of EED symptoms. 
She continued sulfasalazine treatment with success 
Figure 2. A prominent dermal infiltrate is noted in the dermis 
(H&E, 100%).
Figure 3. Neutrophils around dermal blood vessels but no 
features of vasculitis are seen at high magnification (H&E, 200%).
Figure 1. Biopsied lesion on the right fifth digit.
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throughout pregnancy and after delivery without 
reappearance of nodules or other EED symptoms.
Case Discussion
Dapsone is accepted as first-line treatment for EED. 
However, dapsone has proved ineffective in some 
cases [2,3]. This case report suggests sulfasalazine as 
a viable alternative to dapsone.
Sulfasalazine was selected for treatment because it 
is composed of sulfapyradine and 5-aminosalicylic 
acid linked by an azo group, which degenerates into 
its constituent components in the small intestine. 
Sulfapyradine and dapsone share a similar structure 
in that they are both sulfonamides and have similar 
antibiotic and anti-metabolic properties, such as 
inhibiting myeloperoxidase. Dapsone’s efficacy in 
dermatitis herpetiformis and EED is believed to be 
a result of this ability to inhibit myeloperoxidase. 
Because sulfasalazine also has this feature, it was 
selected as a potential replacement of dapsone.
Conclusion
We report a novel treatment approach for EED using 
oral sulfasalazine, which was given to the patient and 
resulted in complete resolution of EED symptoms. 
Although the difference in safety is not explicitly 
proven, and many physicians are comfortable with 
the safety of dapsone in pregnancy, some patients 
may feel more comfortable with sulfasalazine 
(category B) as their medication of choice during 
pregnancy over dapsone (category C).
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